Ropinirole: For the treatment of Restless Legs syndrome

Ropinirole is a non-ergoline dopamine agonist that exhibits a high affinity for D(2) and D(3) receptors but little or no affinity for D(1)-like and non-dopaminergic receptors. Symptoms of restless legs syndrome (RLS) [measured using the International Restless Legs scale and Clinical Global Impressio...

Full description

Saved in:
Bibliographic Details
Published inCNS drugs Vol. 18; no. 11; pp. 747 - 756
Main Authors CHEER, Susan M, BANG, Lynne M, KEATING, Gillian M, ERNST, Michael E, WALTHER, Björn W, WETTER, Thomas C
Format Journal Article
LanguageEnglish
Published Hong Kong Adis International 01.01.2004
Auckland Wolters Kluwer Health, Inc
Subjects
Antiparkinson Agents - administration & dosage
Antiparkinson Agents - pharmacology
Antiparkinson Agents - therapeutic use
Biological and medical sciences
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Tolerance
Humans
Indoles - administration & dosage
Indoles - pharmacology
Indoles - therapeutic use
Medical sciences
Miscellaneous
Neuropharmacology
Pharmacology. Drug treatments
Restless Legs Syndrome - drug therapy
Human
Sensitivity disorder
Agonist
Nervous system diseases
Monograph
Review
Restless legs syndrome
Ropinirole
Chemotherapy
D2 Dopamine receptor
Treatment
Dopamine agonist
Neurological disorder
Mechanism of action
Pharmacokinetics
Online AccessGet full text

Cover

More Information
Summary:Ropinirole is a non-ergoline dopamine agonist that exhibits a high affinity for D(2) and D(3) receptors but little or no affinity for D(1)-like and non-dopaminergic receptors. Symptoms of restless legs syndrome (RLS) [measured using the International Restless Legs scale and Clinical Global Impression-Global Improvement Scale scores] significantly improved with ropinirole compared with placebo in large, randomised, double-blind trials. Ropinirole reduced periodic leg movements and improved sleep efficiency relative to baseline and placebo in several trials (two of which were randomised, double-blind and relatively large) in patients with RLS. Ropinirole was generally well tolerated in patients with RLS; adverse events were generally mild to moderate in nature and consistent with those expected of dopamine agonists. Few patients receiving ropinirole withdrew from therapy because of adverse events, the most predominant of which were nausea and headache.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-3
ObjectType-Review-1
ISSN:1172-7047
1179-1934
DOI:10.2165/00023210-200418110-00004